Investing In The Engine: Why IP Licensing May Be Best Approach For Start-Ups
Executive Summary
Intellectual property infringement – whether intentional or accidental – is becoming a growing threat for start-ups. Medtech Insight spoke to Robert Cote, CEO of COTE Capital, an IP-based investment firm, about how medtechs can both protect their IP and actualize its value.
You may also be interested in...
Investor Eye: A Licensing-Based Approach May Be Best For Revolutionary IP
Keeping a firm grip on one’s IP is a cornerstone of most innovative businesses. However, Robert Cote, CEO of Cote Capital, believes that if the idea is good enough to keep close, it’s good enough to license out.
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.
Deals Shaping The Industry, February 2024
An interactive look at pharma, medtech, and diagnostics deals made during February 2023. Data courtesy of Biomedtracker.